| scholarly article | Q13442814 |
| P50 | author | Roger G Ptak | Q90694284 |
| Dana Gabuzda | Q91131980 | ||
| Marie K Mankowski | Q115679026 | ||
| Vikas Misra | Q124366716 | ||
| Erez Pery | Q124366726 | ||
| Ann Sheehy | Q124366729 | ||
| N Miranda Nebane | Q124366730 | ||
| P2093 | author name string | E Lucile White | |
| Lynn Rasmussen | |||
| Sara J Buhrlage | |||
| Andrew Jay Brazier | |||
| Kottampatty S Rajendran | |||
| P2860 | cites work | T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction | Q24300389 |
| The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA | Q24305266 | ||
| Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. | Q24544264 | ||
| Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication | Q24563503 | ||
| A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion | Q24568052 | ||
| Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent | Q24656023 | ||
| Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly | Q24658171 | ||
| Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation | Q24672209 | ||
| Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells | Q24796626 | ||
| Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification | Q24817186 | ||
| Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses | Q25257798 | ||
| Crystal Structure of the DNA Cytosine Deaminase APOBEC3F: The Catalytically Active and HIV-1 Vif-Binding Domain | Q27678176 | ||
| Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F | Q27680506 | ||
| The APOBEC3C crystal structure and the interface for HIV-1 Vif binding | Q27682427 | ||
| Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein | Q27860488 | ||
| Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts | Q28179446 | ||
| DNA deamination mediates innate immunity to retroviral infection | Q28179534 | ||
| Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif | Q28187133 | ||
| HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability | Q28207304 | ||
| Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex | Q28210666 | ||
| APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication | Q28286241 | ||
| The role of mononuclear phagocytes in HTLV-III/LAV infection | Q29618676 | ||
| HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation | Q29618937 | ||
| The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif | Q29618938 | ||
| Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 | ||
| The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. | Q30333471 | ||
| The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity | Q31011512 | ||
| Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity. | Q33877364 | ||
| Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G | Q33883514 | ||
| Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase | Q33908716 | ||
| Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity. | Q34055413 | ||
| Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC. | Q34179686 | ||
| Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection | Q34242229 | ||
| Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. | Q34651619 | ||
| Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. | Q35214620 | ||
| Role of Vif in human immunodeficiency virus type 1 reverse transcription | Q35873743 | ||
| Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation | Q35914312 | ||
| Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. | Q35947612 | ||
| The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. | Q36099305 | ||
| Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. | Q36315163 | ||
| The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction | Q36484144 | ||
| APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages | Q36506765 | ||
| Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination | Q36559921 | ||
| Subcellular localization of the Vif protein of human immunodeficiency virus type 1. | Q36626506 | ||
| APOBEC-mediated viral restriction: not simply editing? | Q36736677 | ||
| A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor | Q37094645 | ||
| A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). | Q37095343 | ||
| Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif | Q37099703 | ||
| Interactions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-β binding to Vif. | Q37153444 | ||
| Small-molecule inhibition of HIV-1 Vif. | Q37218625 | ||
| Structure-guided analysis of the human APOBEC3-HIV restrictome | Q38198378 | ||
| The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. | Q39405160 | ||
| Structure-based mutagenesis of the human immunodeficiency virus type 1 DNA attachment site: effects on integration and cDNA synthesis. | Q39596337 | ||
| Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. | Q39964772 | ||
| Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. | Q40202838 | ||
| Antiviral potency of APOBEC proteins does not correlate with cytidine deamination | Q40243154 | ||
| A zinc-binding region in Vif binds Cul5 and determines cullin selection | Q40288287 | ||
| APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. | Q40464899 | ||
| Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines | Q40485825 | ||
| Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation | Q40485830 | ||
| Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization | Q40493589 | ||
| Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression | Q40579791 | ||
| A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action | Q40589617 | ||
| Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway | Q40607865 | ||
| Characterization of an HIV-1 Isolate Displaying an Apparent Absence of Virion-Associated Reverse Transcriptase Activity | Q41691433 | ||
| Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding | Q42910736 | ||
| The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G | Q44653976 | ||
| HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation | Q45195765 | ||
| Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity | Q45236572 | ||
| Genetic analysis of HIV-1 isolates from Brazil reveals presence of two distinct genetic subtypes | Q48083097 | ||
| Redoxal as a new lead structure for dihydroorotate dehydrogenase inhibitors: a kinetic study of the inhibition mechanism | Q73422734 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 10504-10517 | |
| P577 | publication date | 2015-02-27 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein | |
| P478 | volume | 290 |
| Q39514817 | 5-Azacytidine Enhances the Mutagenesis of HIV-1 by Reduction to 5-Aza-2'-Deoxycytidine. |
| Q52612280 | A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation. |
| Q39156048 | A Review of Functional Motifs Utilized by Viruses. |
| Q45324625 | APOBEC Enzymes as Targets for Virus and Cancer Therapy. |
| Q28081195 | APOBEC3 Interference during Replication of Viral Genomes |
| Q51011655 | An improved method for purification and refolding of recombinant HIV Vif expressed in Escherichia coli. |
| Q47229846 | Fab-based inhibitors reveal ubiquitin independent functions for HIV Vif neutralization of APOBEC3 restriction factors |
| Q83224530 | Human cytomegalovirus interactome analysis identifies degradation hubs, domain associations and viral protein functions |
| Q40506281 | Identification and characterization of antibacterial compound(s) of cockroaches (Periplaneta americana). |
| Q55380693 | Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation. |
| Q36158234 | Lack of mutational hot spots during decitabine-mediated HIV-1 mutagenesis |
| Q35682519 | Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1. |
| Q92651101 | Regulation of Antiviral Innate Immunity Through APOBEC Ribonucleoprotein Complexes |
| Q60046078 | Restriction Factors: From Intrinsic Viral Restriction to Shaping Cellular Immunity Against HIV-1 |
| Q47568875 | Viral subversion of APOBEC3s: Lessons for anti-tumor immunity and tumor immunotherapy |
Search more.